JP Morgan Chase
KRTX

JP Morgan Chase’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

JP Morgan Chase’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,000
Closed -$2.18M – 7436
2023
Q1 		$2.18M Buy
+12,000
New +$2.3M ﹤0.01% 3482
2022
Q4 		– Sell
-3,800
Closed -$855K – 7144
2022
Q3 		$855K Buy
+3,800
New +$769K ﹤0.01% 4120

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

JP Morgan Chase's KRTX Position: Q1 2024 in Review

JP Morgan Chase sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 30,552 shares — an estimated $9.67M sold.

JP Morgan Chase first reported a position in KRTX in Q2 2019 and held it in 19 quarters. The position peaked at $13.4M in Q2 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • JP Morgan Chase reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • JP Morgan Chase sold 30,552 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $9.67M.
  • JP Morgan Chase first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 19 quarters.
  • JP Morgan Chase's Karuna Therapeutics, Inc. Common Stock position peaked at $13.4M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.